An Ultrasensitive Assay for Measurement of Levels of Cathepsin B in the Blood
By LabMedica International staff writers Posted on 21 Apr 2021 |

Image: Representation of the molecular structure of the cathepsin B (catB) protein (Photo courtesy of Wikimedia Commons)
A novel digital enzyme-linked immunosorbent assay (ELISA) has been developed for the differential detection of cathepsin B from samples of serum or plasma.
Cathepsin B (catB) is a lysosomal cysteine protease expressed in various cells and organs, where it plays a role in protein degradation and turnover. Under pathological conditions, catB expression becomes upregulated in a variety of diseases including metastatic cancers, infections, traumatic brain injury, and neurological diseases. This upregulation is often associated with increased extracellular secretion via active or passive mechanisms. As such, the catB protein content is elevated above basal levels where it may have utility as a biofluid-based marker of diseases, injury, or trauma.
While biofluid samples such as plasma and serum contain catB, it is often difficult to obtain accurate measurements of the protein due to background interference and high variance, which limit the usefulness of catB as a peripheral biomarker. Thus, techniques for ultrasensitive protein detection that require low volumes of sample are necessary.
In this regard, investigators at Walter Reed Army Institute for Research (Silver Spring, MD, USA) developed a digital ELISA for differential detection of catB within less than five microliters of serum and plasma using the single molecule array (SiMoA) platform, which offers 1000-times more sensitivity and vastly reduced variance compared to colorimetric tests.
Results revealed that in buffer solution, the limit of detection (LoD) was between 1.56 and 8.47 picograms per milliliter depending on whether a two-step or three-step assay was used. After correcting for endogenous levels, the estimated LoD was approximately 4.7 picograms per milliliter in serum or plasma with the two-step assay. The lower limit of quantitation was about 2.3 picograms per milliliter in buffer and about 9.4 picograms per milliliter in serum or plasma, indicting the ability to measure small changes above endogenous levels within blood samples.
"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said first author Dr. Bharani Thangavelu, a researcher in the brain trauma neuroprotection branch at the Walter Reed Army Institute for Research. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."
The ultrasensitive ELISA for cathepsin B was described in the March 31, 2021, online edition of the journal ACS Omega.
Related Links:
Walter Reed Army Institute for Research
Cathepsin B (catB) is a lysosomal cysteine protease expressed in various cells and organs, where it plays a role in protein degradation and turnover. Under pathological conditions, catB expression becomes upregulated in a variety of diseases including metastatic cancers, infections, traumatic brain injury, and neurological diseases. This upregulation is often associated with increased extracellular secretion via active or passive mechanisms. As such, the catB protein content is elevated above basal levels where it may have utility as a biofluid-based marker of diseases, injury, or trauma.
While biofluid samples such as plasma and serum contain catB, it is often difficult to obtain accurate measurements of the protein due to background interference and high variance, which limit the usefulness of catB as a peripheral biomarker. Thus, techniques for ultrasensitive protein detection that require low volumes of sample are necessary.
In this regard, investigators at Walter Reed Army Institute for Research (Silver Spring, MD, USA) developed a digital ELISA for differential detection of catB within less than five microliters of serum and plasma using the single molecule array (SiMoA) platform, which offers 1000-times more sensitivity and vastly reduced variance compared to colorimetric tests.
Results revealed that in buffer solution, the limit of detection (LoD) was between 1.56 and 8.47 picograms per milliliter depending on whether a two-step or three-step assay was used. After correcting for endogenous levels, the estimated LoD was approximately 4.7 picograms per milliliter in serum or plasma with the two-step assay. The lower limit of quantitation was about 2.3 picograms per milliliter in buffer and about 9.4 picograms per milliliter in serum or plasma, indicting the ability to measure small changes above endogenous levels within blood samples.
"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said first author Dr. Bharani Thangavelu, a researcher in the brain trauma neuroprotection branch at the Walter Reed Army Institute for Research. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."
The ultrasensitive ELISA for cathepsin B was described in the March 31, 2021, online edition of the journal ACS Omega.
Related Links:
Walter Reed Army Institute for Research
Latest Molecular Diagnostics News
- Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear
- First-of-Its-Kind Blood Test Detects Over 50 Cancer Types
- Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk
- Single Cell RNA Sequencing Could Enable Non-Invasive Blood Disorder Diagnosis
- Blood Test Identifies HPV-Associated Head and Neck Cancers 10 Years Before Symptoms
- Giant DNA Elements Discovered in Mouth Could Impact Oral Health
- Simple Blood Test Spots Disease Through Metabolic Distortion
- Simple Blood Test Could Streamline Early Alzheimer's Detection
- Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer
- ELISA-Based Test Uses Gynecologic Fluids to Detect Endometrial Cancer
- Comprehensive Tumor Profiling Kit Decentralizes and Standardizes Oncology Testing
- Automated Syndromic Testing System Combines Unparalleled Throughput with Simple Workflow
- Simple Urine Test Assesses Risk of Kidney Cancer Recurrence at Early Stage
- Molecular Map Reveals Previously Hidden Connections Between Diseases
- Novel Urine-Based Test Detects Prostate Cancers
- MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence
Channels
Clinical Chemistry
view channel
Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. Current approaches make it difficult to accurately... Read more
Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read moreHematology
view channel
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read moreImmunology
view channel
Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more
Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more
Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more
Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read moreMicrobiology
view channel
Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Sepsis arises from infection and immune dysregulation, with neutrophils playing a central role in its progression. However, current clinical tools are unable to both isolate these cells and assess their... Read more
New Diagnostic Method Confirms Sepsis Infections Earlier
Sepsis remains one of the most dangerous medical emergencies, often progressing rapidly and becoming fatal without timely intervention. Each hour of delayed treatment in septic shock reduces patient survival... Read more
New Markers Could Predict Risk of Severe Chlamydia Infection
Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
Vaginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications,... Read morePathology
view channel
Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma
Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification
High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical... Read moreTechnology
view channel
Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
Respiratory tract infections (LRTIs) are leading causes of illness and death worldwide, particularly among vulnerable populations such as the elderly, young children, and those with compromised immune systems.... Read moreIndustry
view channel
Werfen and VolitionRx Partner to Advance Diagnostic Testing for Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a rare autoimmune disorder that causes the immune system to produce abnormal antibodies, making the blood “stickier” than normal. This condition increases the risk of... Read more